| 抗骨质疏松药物作用机制及在研药物研究进展 |
| Mechanisms of action of anti-osteoporotic drugs and research advances in emerging therapeutics for osteoporosis |
| 投稿时间：2024-09-23 |
| DOI：10.3969/j.issn.1672-5972.2026.01.012 |
| 中文关键词: 骨质疏松症 作用机制 促骨形成 抗骨吸收 抗骨质疏松药物 |
| 英文关键词:Osteoporosis Anti-osteoporotic mechanisms Bone formation promotion Bone resorption inhibition Anti-osteoporotic drugs |
| 基金项目: |
| 作者 | 单位 | 邮编 | | 高增杰* | 北京积水潭医院贵州医院骨科,贵州 贵阳,550014
贵州中医药大学,贵州 贵阳,550025 | 550025 | | 李来来 | 贵州中医药大学,贵州 贵阳,550025 | 550025 | | 黄华 | 北京积水潭医院贵州医院骨科,贵州 贵阳,550014 | 550014 | | 覃裕 | 北京积水潭医院贵州医院骨科,贵州 贵阳,550014 | 550014 |
|
| 摘要点击次数: 13 |
| 全文下载次数: 1 |
| 中文摘要: |
| 骨质疏松症是一种全球范围内高发的老龄性疾病，危害性极大。骨吸收与骨形成失衡是骨质疏松症发病的主要机制，涉及炎症因子、RANK/RANKL/OPG系统、SOST/Wnt/β-catenin等多种细胞因子、激素及信号通路。抗骨质疏松药物主要的作用机制是抑制骨吸收、促进骨形成及改善骨矿化。本文系统综述了抗骨质疏松药物促骨形成、抑制骨吸收发挥调控骨代谢的作用机制，并对主流及在研药物的机制、靶点进行了探讨，以期为临床及科研提供参考。 |
| 英文摘要: |
| Osteoporosis is a highly prevalent age-related disease worldwide, posing significant health risks. The primary pathogenic mechanism of osteoporosis involves an imbalance between bone resorption and bone formation, mediated by various cytokines, hormones, and signaling pathways—including inflammatory factors, the RANK/RANKL/OPG system, and the SOST/Wnt/β-catenin pathway. Anti-osteoporotic drugs primarily act by inhibiting bone resorption, promoting bone formation, and enhancing bone mineralization. This article provides a systematic review of the mechanisms by which anti-osteoporotic agents regulate bone metabolism—specifically through promoting bone formation and suppressing bone resorption—and discusses the mechanisms and molecular targets of both established and investigational therapeutics, aiming to offer valuable insights for clinical practice and research. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
